A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease

Neurology

Volumn 53, Issue 2, 1999, Pages 364-370

  Korczyn, Amos D ^d   Brunt, E R ^e   Larsen, J P ^a   Nagy, Z ^b   Poewe, H ^e   Ruggieri, S ^c  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b National Stroke Centre   (Hungary)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d TEL AVIV UNIVERSITY   (Israel)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; ROPINIROLE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; HUMAN; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT OUTCOME;

EID: 0033595201     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.2.364     Document Type: Article

References (18)

1. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997;49: 393-399.
2. Shannon KM, Bennett JP, Friedman JH, for the Pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997;49:724-728.
3. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-828.
4. Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 1989;39:336-339.
5. Hely MA, Morris JGL, Reid WGJ, et al. The Sydney multicentre study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose L-dopa-carbidopa. J Neurol Neurosurg Psychiatry 1994; 57:903-910.
6. Wolters EC, Tissingh G, Bergmans PLM, Kuiper MA. Dopamine agonists in Parkinson's disease. Neurology 1995; 45(suppl 3):S28-S34.
7. Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year L-dopa-controlled study. Mov Disord 1998;13:39-45.
8. 2 agonist. Pharmacol Biochem Behav 1991;38:147-154.
9. Roos RAC, Vredevoogd CB, van der Velde EA. Response fluctuations in Parkinson's disease. Neurology 1990;40:1344-1346.
10. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow-up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038.
11. Korczyn AD, Brooks DJ, Brunt ER, et al. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. Mov Disord 1998;13: 46-51.
12. Fahn S, Elton RL, UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, et al., eds. Recent developments in Parkinson's disease, vol 2. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-163.
13. Richards M, Marder K, Cote L, Mayeux R. Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination. Mov Disord 1994;9:89-91.
14. Laroche J. An alternative analysis of motor score in the assessment of Parkinson's disease. In: Douglas J, Ciba Pharmaceuticals, ed. 1995 PSI Conference report, Blackpool, UK. Macclesfield, UK: PSI Statisticians in the Pharmaceutical Industry, 1995:52-53.
15. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997;48:363-368.
16. UK Bromocriptine Research Group. Bromocriptine in Parkinson's disease: a double-blind study comparing "low-slow" and "high-fast" introductory dosage regimens in de novo patients. J Neurol Neurosurg Psychiatry 1989;52:77-82.
17. Bergamasco B, Benna P, Scarzella L. Long-term bromocriptine treatment of de novo patients with Parkinson's disease. A seven-year follow-up. Acta Neurol Scand 1990;81:383-387.
18. Montastruc JL, Rascol O, Rascol A. A randomised controlled study of bromocriptine versus L-dopa in previously untreated Parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry 1989;52:773-775.